In early December the American Society of Hematology (ASH) hosted its 59th Annual Meeting and Exposition in which over 25,000 attendees gathered to discuss the latest data from over 5,000 abstracts.
As part of the ASH Annual Meeting & Exposition, PER® was thrilled to host three diverse satellite symposia:
- Current and Emerging Strategies to Evolve the Standard of Care for Patients with GVHD
- Evaluating the Emerging Role of Biosimilar Agents for the Treatment of Hematologic Malignancies
- Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies
When this much data comes out at once, it can be hard to decipher. What you need to know will be presented at International Congress on Hematologic Malignancies®.
